



(51) International Patent Classification:

C07K 14/705 (2006.01) **C12N 5/078** (2010.01)
A61K 38/20 (2006.01) **C12N 5/0783** (2010.01)
A61K 39/00 (2006.01) **C12N 5/0784** (2010.01)
A61P 35/00 (2006.01) **C12N 15/12** (2006.01)
C07K 7/06 (2006.01) **C12Q 1/6809** (2018.01)
C07K 14/00 (2006.01) **G01N 33/48** (2006.01)
C12N 5/07 (2010.01) **G01N 33/68** (2006.01)

(21) International Application Number:

PCT/CA2022/051377

(22) International Filing Date:

16 September 2022 (16.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/261,315 17 September 2021 (17.09.2021) US

(71) Applicant: **UNIVERSITÉ DE MONTRÉAL** [CA/CA];
2900 boul. Édouard-Montpetit, Montréal, Québec H3T 1J4 (CA).

(72) Inventors: **PERREAULT, Claude**; 70 avenue Claude-Champagne, Montréal, Québec H2V 2X1 (CA). **THIBAUT, Pierre**; 8560 rue Joseph-Quintal, Montréal, Québec H2M 2M8 (CA). **CLEYLE, Jenna**; 106 Campbell Crescent, Fort McMurray, Alberta T9K 2N3 (CA). **HARDY, Marie-pierre**; 618 rue de Bétusy, Terrebonne, Québec J6Y 0A5 (CA).

(74) Agent: **LAVERY, DE BILLY, LLP**; 1, Place Ville Marie, Bureau 4000, Montréal, Québec H3B 4M4 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,

(54) Title: NOVEL TUMOR-SPECIFIC ANTIGENS FOR COLORECTAL CANCER AND USES THEREOF




FIG. 13

(57) Abstract: Colorectal cancer (CRC) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) expressed by CRC cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells, antibodies and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, antibodies, cells and vaccines for the treatment of CRC is also described.

[Continued on next page]

LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*